Items
Tag is exactly
clinical trial
-
2022-05-03
Nose Spray Vaccines Could Quash COVID Virus Variants
This is a news story from The Scientific American by Marla Broadfoot. With the effectiveness of vaccines waning due to new variants coming about, scientists have been coming up with new ways to combat the virus. Scientists are thinking of developing a nose spray vaccine that attacks the virus at the source. It is believed that a vaccine delivered this method could trigger mucosal immunity. Nasal vaccines have been shown in the past to be more effective than traditional administration of vaccines. There is risk in this, however, because there still needs to be more research done on mucosal immunity. The advantage is that this vaccine does not rely on syringes or needles, so it has the possibility of reaching more people. -
2021-04-17
13-year-old in Pfizer Covid vaccine trial who wants to be an epidemiologist: ‘I like to learn everything I can’
Recently CNBC has released an article on my story in the Pfizer Vaccine Trial. I got interviewed about a week ago, and I helped in the making of the article. It is on a division of CNBC called CNBC Make It. CNBC Make It is a section of CNBC that specializes in money, wellness, and heartwarming stories. I have gotten to know the writer, Cory Stieg, well and it was great working with her. The article goes into detail about how the trial works and my experience with the trial. This experience has been amazing from both ends, Pfizer and CNBC. I hope that I inspired others to make a change in the world and to try and pursue your passions. Link to article in description -
2020-11-19
新型コロナ治療に光 ウイルス侵入防ぐ物質を開発(2020年11月19日) - Developed a substance to prevent invasion of light virus for new corona treatment (November 19, 2020)
新型コロナウイルスの有力な治療薬になる可能性があります。京都府立医科大学などの研究チームは新型コロナウイルスが細胞に侵入するのを防ぐ特殊なたんぱく質を開発したと発表しました。 京都府立医科大学・星野温助教:「(新型コロナウイルス)治療薬がまだ『これ』というのが確立されてませんので、その一つの大きな候補となる開発技術になりますので、大きく社会に貢献できるものと期待します」 新型コロナウイルスは表面にあるトゲが人の細胞の表面にある「ACE2」と呼ばれる突起と結合することで細胞内に侵入します。京都府立医科大学の星野温助教らの研究チームは細胞の突起に結合する前に、ウイルス表面のトゲと結合する特殊なたんぱく質を開発しました。トゲと結合する力がACE2よりも100倍以上強いということです。このたんぱく質を軽症や中等症の患者に投与することで感染した後に症状の悪化を抑える効果が期待できるということです。また、似たような仕組みの抗体製剤と比べてウイルスが変異しても効果が変わらないとしています。 京都府立医科大学・星野温助教:「抗体製剤は比較的スパイク(ウイルスのトゲ)と点でくっついている感じですね。私たちのたんぱく質製剤は元々、スパイクがACE2(細胞の突起)にくっつく面をすべてカバーしているので」 今後は企業と協力して来年度に臨床試験を始め、再来年度の実用化を目指したいとしています。 It has the potential to be a powerful remedy for the new coronavirus. Research teams including Kyoto Prefectural University of Medicine have announced that they have developed a special protein that prevents the new coronavirus from invading cells. Assistant Professor Atsushi Hoshino, Kyoto Prefectural University of Medicine: "(New coronavirus) Therapeutic drug has not yet been established, so it will be one of the major candidates for development technology, and will greatly contribute to society. I expect it to be possible. " The new coronavirus invades the cells by binding the spikes on the surface to the protrusions called "ACE2" on the surface of human cells. A research team led by Assistant Professor Atsushi Hoshino of Kyoto Prefectural University of Medicine has developed a special protein that binds to spikes on the surface of the virus before it binds to the protrusions of cells. It means that the force to bind to spikes is more than 100 times stronger than ACE2. By administering this protein to patients with mild or moderate illness, it can be expected to have the effect of suppressing the worsening of symptoms after infection. In addition, compared to antibody preparations with a similar mechanism, the effect does not change even if the virus mutates. Atsushi Hoshino, Assistant Professor, Kyoto Prefectural University of Medicine: "It feels like antibody preparations are relatively sticking to spikes (virus spikes). Our protein preparations already have spikes sticking to ACE2 (cell protrusions) and it covers all of them. " In the future, we would like to cooperate with companies to start clinical trials next year and aim for practical application in the following year of next year. Video translated by Youngbin Noh -
2019-10-13
コロナワクチン治験中断 参加者が原因不明の病気 米J&J(2020年10月13日)- Corona vaccine clinical trial suspended. Illness of unknown cause by participants. US J & J (October 13, 2020)
This news is about the stop of clinical trials of the vaccine for COVID-19 virus. I personally was really suspicious about these vaccine because the process is moving too fast and usually vaccine development can take years to be used to the public. アメリカの製薬大手ジョンソン・エンド・ジョンソンは12日、新型コロナウイルスワクチンの全ての治験を一時停止したと発表しました。 治験の参加者1人が原因不明の病気になったのが理由としていますが、症状など具体的な情報は明らかにしていません。 新型コロナワクチンをめぐっては、日本も供給を受けることで合意をしているイギリスのアストラゼネカが9月、副作用の疑いがあるとして、世界的な治験中断に一時追い込まれました。 American pharmaceutical company Johnson & Johnson announced on the 12th that it has suspended all clinical trials of the new coronavirus vaccine. The reason is that one of the participants in the clinical trial became ill with an unknown cause, but specific information such as the symptoms has not been disclosed. In September, AstraZeneca of the United Kingdom, which has agreed to supply Japan with the new corona vaccine, was temporarily suspended from clinical trials worldwide because of suspected side effects. -
2020-10-13
Vaccine trials on hold
CNN reports that Johnson and Johnson put their vaccine trials on pause after one of their volunteers is experiencing an unexplained illness. As if many people weren’t already sketched out about this vaccine race this is yet another reason why many are saying they’ll wait a while to get vaccinated. I for one, will wait until it’s ok’d by the CDC and the first wave of people vaccinated don’t have adverse reactions. -
4/22/2020
Robert Graham Oral History, 2020/04/22
Theodora Christopher interviews Robert Graham whose background is in pediatric ICU respiratory treatment. He discusses COVID-19 and its effect on children and adults and the difference in number of cases in different locations. He also discusses the effect COVID has had on facilitating clinical trial, etc.